Plenary Speakers

Professor Diona Damian

Diona Damian is Professor of Dermatology at the University of Sydney, Clinical Academic at Royal Prince Alfred Hospital and Associate of the Melanoma Institute Australia. Her research focuses on the role of skin immunity in the mechanisms, prevention and treatment of skin cancer.

Professor Christoph Hoeller

More information will be available soon.

Doctor Henry W. Lim

Henry W. Lim MD, is the Chair Emeritus of the Department of Dermatology, Henry Ford Hospital, and Senior Vice President for Academic Affairs, Henry Ford Health System, Detroit, Michigan, USA.  He stepped down from the chairmanship of the dermatology department on March 1, 2017 as he assumes the president position of the American Academy of Dermatology.

He received his M.D. (cum laude) from SUNY Downstate Medical Center, Brooklyn, New York, USA, and completed his dermatology residency at New York University School of Medicine.  Prior to coming to Henry Ford Hospital, he was a Professor of Dermatology at NYU School of Medicine, as well as the Chief of Staff of the New York VA Medical Center.  He has published more than 400 articles and edited 7 textbooks.   He is a recognized world authority on photodermatology.  He has been on Best Doctors list annually since 1994.

Dr. Lim has served as president of Michigan Dermatological Society, vice president of the American Academy of Dermatology, president of the American Board of Dermatology, and president of the American Dermatological Association.  From March 2017 to Feb 2018, he was the president of the American Academy of Dermatology, the world’s largest dermatologic society. In 2016, he was selected as the recipient of the Fred W. Whitehouse, MD, Distinguish Career Award of the Henry Ford Medical Group.

He was an Associate Editor of the Journal of Investigative Dermatology, and was Editor-in-Chief of Photodermatology, Photoimmunology & Photomedicine. He is currently a Senior Editor of Journal of Drugs in Dermatology, and a member of the editorial board of Photodermatology, Photoimmunology, and Photomedicine.  He was a former editorial board member of Journal of Investigative Dermatology, Journal of the American Academy of Dermatology, and JAMA Dermatology. He is an elected honorary member of dermatology societies in Austria, France, Spain, the Philippines, China, and the Baltics. 


Professor Georgina Long

Professor Georgina Long, BSc PhD MBBS FRACP, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premiers Awards for Outstanding Cancer Research. In 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011; and in 2013 she was named the Outstanding Cancer Research Fellow.

She is the author of over 160 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 120 occasions. She is President-elect for the prestigious international Society for Melanoma Research (President from 2018), is member (2015-2017) and Chair (2016) of the ASCO Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

Professor Stephen Mulligan

More information will be available soon.

Professor Richard Scolyer

Professor Richard Scolyer is Co-Medical Director of Melanoma Institute Australia; He is also Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney. Professor Scolyer studied medicine at the University of Tasmania. After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. Professor Scolyer has presented on more than 250 occasions at conferences throughout the world, and is a co-author of more than 500 articles and book chapters on melanocytic pathology and related research including publications in New England Journal of Medicine, Lancet, Nature, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. In 2006, Professor Scolyer was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received a NSW Premier’s Award for Outstanding Cancer Research in 2009 and 2012, and the Thomson Reuters 2015 Citation Award in the Clinical Medicine category. In 2016, Professor Scolyer was appointed editor of the 4th Edition of the World Health Organisation Classification of Tumours Skin Tumours volume. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of the AJCC Cancer Staging System, Co-lead of the Australian Melanoma Genome Project, an editorial board member of the American Journal of Surgical Pathology, Melanoma Research and Melanoma Management, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology. Professor Scolyer is Immediate Past President of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Professor Scolyer is chief investigator on a 5-year NHMRC program grant and has a personal Fellowship from the NHMRC.

Professor Craig Sinclair

Professor Craig Sinclair is one of Australia’s leading experts on skin cancer prevention. Mr Sinclair is the Director of the World Health Organisation’s (WHO) Collaborative Centre for UV Radiation and has particular expertise in skin cancer, vitamin D and sun protection.

As chair of Cancer Council Australia’s Public Health and Skin Cancer Committees and Head of Prevention at Cancer Council Victoria, Mr Sinclair is also an expert media commentator on a broad range of public health issues related to cancer prevention including obesity, alcohol and cancer screening. He is an author of over 30 peer reviewed publications including the WHO’s Risks and Guidance Note on Artificial Tanning Sunbeds.

Professor H. Peter Soyer MD, FACD, FAHMS

Professor H. Peter Soyer has a dual academic/clinical role as the inaugural Chair and Director of the Dermatology Research Centre, The University of Queensland (UQ) Diamantina Institute, at the Translational Research Institute, and as Director of the Dermatology Department at the Princess Alexandra Hospital. Professor Soyer, an academic dermatologist from Austria, is a world leader in the field of dermatology with particular expertise in the areas of dermatooncology and dermatologic imaging. His research group’s main focus is skin cancer (both keratinocyte skin cancer and melanoma), and he is co-inventor in patents for novel skin delivery platforms and microbiospy sampling devices. He has an extensive publication record with over 500 publications (>120 publications in the last 5 years), over 600 citations a year and a Hirsch index of 48 (Researcher ID). In 2016 he initiated establishment and is Co-leader of the Australian Skin and Skin Cancer (ASSC) Research Centre, a joint venture between UQ and QIMR Berghofer Medical Research Institute. He is one of three Congress Presidents for the 9th World Congress of Melanoma, being held in Brisbane in October 2017. He is lead investigator of the Centre of Research Excellence for the Study of Naevi funded by the Australian Government National Health and Medical Research Council (NHMRC), a Queensland Genomics Health Alliance Demonstration Project ‘A Genomics Approach for Screening of Patients at High Risk of Melanoma’, and a UQ Faculty of Medicine Health Outcome Program ‘3D QMelanoma – Targeted Early Detection of Melanoma Utilising a 3D Teledermatology Network’.

Associate Professor Louisa Gordon

Associate Professor Louisa Gordon is Team Head of Health Economics at QIMR Berghofer Medical Research Institute. Louisa is a health economist and holds a PhD in Public Health, Masters of Public Health and Bachelor of Economics. Louisa has 15 years research experience as a health economist performing economic evaluations, decision-analytic modelling and applied economic research. She has a track record in the areas of skin cancer prevention, supportive care interventions for cancer survivors, costing studies and the financial impacts of cancer among patients.

Thank you for attending WCCS 2018

Please view the below presentations.
For more presentations, email the Congress Managers.